Cardiol Therapeutics (CRDL) Issues Year-end Update on Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Cardiol Therapeutics Announces Year-End 2024 Update on Operations
April 1, 2025 7:29 AM UTCReported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx" administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial
Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx" in patients
with acute myocarditis, with topline data expected in Q2 2025
CardiolRx" granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,
which includes recurrent pericarditis
Cash and cash equivalents of $30.6 million as of December 31, 2024,
to fund operations into Q3... More
